Analysis

Breast cancer therapy – what’s preventing better treatments?

Oncologists, clinical leads, pharmacists and research fellows at the Breast Cancer Drugs Funding and Trials event earlier this year discussed how effective the current breast cancer drugs regime is and how the NHS can ensure new drugs reach patients.

Oncologists, clinical leads, pharmacists and research fellows at the Breast Cancer Drugs Funding and Trials event earlier this year discussed how effective the current breast cancer drugs regimen is and how the NHS can ensure new drugs reach patients

Britain’s breast cancer patients are losing out, breast cancer charity Pink Ribbon Foundation warned. Current therapies for breast cancer are inadequate and in the past year, Britain’s breast cancer patients have lost out on treatment options, as rising drug costs make breast cancer drugs unaffordable for stretched NHS budgets.

As an example, in April, the drug nivolumab was not considered a cost-effective use of NHS resources at £63,200 a year per patient despite being clinically effective, Imperial College London junior research fellow Aleksandra Filipovic informed attendees. While in December 2016, NICE

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs